Explore recent FDA enforcement trends and the agency’s current focus, and consider potential priorities under the incoming Trump Administration.
CMS sought far-reaching changes to the Medicaid Drug Rebate Program in its 2023 proposed rule implementing the Medicaid Services Investment and Accountability Act. Find out which proposals CMS dropped from the final rule, and which changes became effective November 19, 2024.
One of the year’s major drug pricing conferences just concluded in Chicago. Join the Latham team to discuss takeaways from the conference, including highlights from remarks by government speakers.
Recent Supreme Court decisions, such as those overruling Chevron deference, as well as ongoing manufacturer challenges to the Inflation Reduction Act and state 340B laws, will likely have a significant impact on the pharmaceutical industry.
Explore how health insurance companies are adapting to the Inflation Reduction Act's new requirements, including the Part D redesign.
One of the year’s major drug pricing conferences just concluded in New Orleans. Join the Latham team to discuss takeaways from the conference, with topics including 340B developments, state legislative activity, and IRA implementation.
The new ASP reporting website highlights the increasing significance of data collection portals — and yet the number of permitted users is very small. Join us as we learn from leading practitioners at Riparian how to navigate the complex web of compliance requirements.
Listen to this “lightning round” to hear how the policy and regulatory environment will likely remain hostile for pharmaceutical manufacturers, and how to address the turbulence that lies ahead.
A new proposal seeks to reinvigorate the Bayh-Dole Act by allowing government to consider price as a factor when electing to exercise march-in rights.
Hear from Latham attorneys and a leading industry practitioner what the OIG compliance guidance means for drug manufacturers.
Industry stakeholders shone a light on recent agency actions as the Inflation Reduction Act’s drug price negotiations proceed.
A proposed rule would alter best price stacking requirements, while the Inflation Reduction Act includes negotiated maximum fair prices in best price.
Recent developments point to an emerging policy focus on establishing single payment rates for therapeutic classes and not for individual drugs.
Emerging companies in the energy tech sector present attractive investment opportunities, and unique challenges, as they innovate across the energy supply chain.
Sustainable finance’s availability and reputation may offer an attractive financing alternative to finance the energy transition.
With half the world’s population and soon three billion mobile subscribers, the Asia Pacific region is set for long-term growth in digital infrastructure.
As activism campaigns increasingly incorporate ESG issues, we discuss how companies can prepare for and navigate such shareholder-led challenges.
As European majors diversify and accelerate the energy transition, the market can expect continued consolidation, including across borders.
As the Biden Administration ramps up its investment in renewables, we speak with the head of the DOE Loan Programs Office about the practical realities companies should consider when applying for a loan guarantee.
Project sponsors and lenders should be aware of significant recent changes to due diligence and monitoring standards that are part of EP4.
The popularity of sustainability-linked bonds offers companies new capital raising options in the debt markets.
Federal climate action aims to accelerate the transition to clean energy, with major changes affecting nearly every aspect of the industry.
As the energy markets transition to more renewable energy sources, a mix of investor interest, market forces, and tax credits will channel capital into specific industry sectors.